Represents the number of performance obligation.

No definition available.

Name:	tbph_RevenueRemainingPerformanceObligationNumberOfPerformanceObligations
Namespace Prefix:	tbph_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=tbph_MylanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=tbph_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=tbph_DevelopmentAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tbph_YupelriMonotherapyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=tbph_EuropeanUnionRegulatoryIssuesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tbph_FuturePotentialCombinationProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=tbph_PfizerInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue - Revenue from Licensing Arrangements (Details) $ in Thousands	1 Months Ended			3 Months Ended			6 Months Ended
	Dec. 31, 2019 USD ($) plan	Jun. 30, 2019 USD ($)	Jan. 31, 2015 plan	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2020 USD ($)
Collaborative Arrangements and Co-Promote Agreement
Milestone payment				$ 15,008		$ 26,150	$ 34,870	$ 31,488
Mylan
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments									$ 1,500
Upfront payment receivable		$ 18,500
Number of performance obligations \| plan			2
Mylan \| Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments		37,500				37,500		37,500
Mylan \| Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments				205,000			205,000
Mylan \| YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments		9,000				9,000		9,000
Mylan \| YUPELRI Monotherapy \| Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments				150,000			150,000
Mylan \| YUPELRI Monotherapy \| Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments				160,000			160,000
Mylan \| YUPELRI Monotherapy \| European Union Regulatory Issues [Member]
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments				10,000			10,000
Mylan \| Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments		7,500		$ 45,000		7,500	$ 45,000	7,500
Mylan \| Future potential combination products \| Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments		$ 54,000				$ 54,000		$ 54,000
Pfizer
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 10,000				$ 10,000
Number of performance obligations \| plan	2
Pfizer \| Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment	$ 240,000